SALT LAKE CITY, Sept. 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Gilmartin Group Annual Emerging Growth Showcase.
Dwight Egan, Company CEO, will be participating in a fireside chat discussing Company progress on its forthcoming Co-Dx PCR Home™ platform on Thursday, September 21 at 11:00 AM ET. The discussion can be accessed virtually through the Events and Webcasts section of the Co-Diagnostics website.
The Co-Dx PCR Home platform is subject to FDA review and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-gilmartin-group-annual-emerging-growth-showcase-on-sept-21-301934872.html
SOURCE Co-Diagnostics
